MediciNova, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yuichi Iwaki
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4275 Executive Square La Jolla CA United States of America 92037
- IPO Date
- Dec 8, 2006
- CIK
- 0001226616
- Website
- medicinova.com
- Similar Companies
- Business
- MediciNova, Inc. is a biopharmaceutical firm dedicated to the discovery and advancement of innovative small-molecule therapies for severe medical conditions addressing significant unmet needs, primarily in the United States. The company's pipeline features MN-166 (ibudilast), an oral compound exhibiting both anti-inflammatory and neuroprotective effects, currently undergoing advanced development for various neurological conditions. This includes treatment for progressive multiple sclerosis, where it is Phase 3-ready and has secured relevant patents, as well as amyotrophic lateral sclerosis (ALS), for which its Phase 2b/3 COMBAT-ALS clinical trial recently completed enrollment, with an Expanded Access Program also underway, supported by NIH funding. Further indications for MN-166 extend to chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, Long COVID, substance dependence and addiction, and the prevention of acute respiratory distress syndrome. Another key candidate is MN-001 (tipelukast), an orally available small molecule targeting fibrotic and metabolic disorders. It is being investigated for conditions such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, with a Phase 2 trial recently completing enrollment for the latter. The pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for managing acute exacerbations of asthma and chronic obstructive pulmonary disease. Additionally, MN-029 (denibulin), a vascular-disrupting agent, has completed Phase 1 studies for the treatment of solid tumor cancers. MediciNova leverages strategic collaborations, predominantly with Japanese pharmaceutical entities, to advance its diversified portfolio. The company, established in 2000, maintains its headquarters in La Jolla, California.
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened
MediciNova to Participate at the 38th Annual ROTH Conference
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts
VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis
2026 New Year's Greetings from the CEO
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
MediciNova Provides Shareholder Update on Key Developments
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million